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Abstract 
Genome-wide association studies (GWAS) identify genetic variants associated with quantitative traits 
or disease. Thus, GWAS never directly link variants to regulatory mechanisms, which, in turn, are 
typically inferred during post-hoc analyses. In parallel, a recent deep learning-based method allows 
for prediction of regulatory effects per variant on currently up to 1,000 cell type-specific chromatin 
features. We here describe “DeepWAS”, a new approach that directly integrates predictions of these 
regulatory effects of single variants into a multivariate GWAS setting. As a result, single variants 
associated with a trait or disease are, by design, coupled to their impact on a chromatin feature in a 
cell type. Up to 40,000 regulatory single-nucleotide polymorphisms (SNPs) were associated with 
multiple sclerosis (MS, 4,888 cases and 10,395 controls), major depressive disorder (MDD, 1,475 
cases and 2,144 controls), and height (5,974 individuals) to each identify 43-61 regulatory SNPs, 
called deepSNPs, which are shown to reach at least nominal significance in large GWAS. MS- and 
height-specific deepSNPs resided in active chromatin and introns, whereas MDD-specific deepSNPs 
located mostly to intragenic regions and repressive chromatin states. We found deepSNPs to be 
enriched in public or cohort-matched expression and methylation quantitative trait loci and 
demonstrate the potential of the DeepWAS method to directly generate testable functional hypotheses 
based on genotype data alone. DeepWAS is an innovative GWAS approach with the power to identify 
individual SNPs in non-coding regions with gene regulatory capacity with a joint contribution to 
disease risk. DeepWAS is available at https://github.com/cellmapslab/DeepWAS.  
Background 
Genome-wide association studies (GWAS) have been highly successful in identifying genetic variants 
associated with risk for common diseases and traits 1. However, going from pure association to 
mechanistic insight has been a much more challenging task. Identification of the true causal variants 
in the context of a disease or trait from within regions of associated variants is hampered by linkage 
disequilibrium (LD), as nearby variants are likely to co-segregate in a population. The functional 
variants can, in most cases, not be easily discerned within long stretches of such correlated DNA, 
which can span several genes and include hundreds of associated variants.  
 
Additional post-processing approaches, so called functional GWAS, have been introduced to provide 
missing functional annotation to classical GWAS 2. The majority of published functional GWASs are 
based on the positional overlap of single-nucleotide polymorphisms (SNPs) with cis-regulatory 
elements such as promoters and enhancers (see Tak and Farnham 3 for a comprehensive review). 
These functional GWASs indicate that, for common diseases, the majority of associated SNPs reside 
in non-coding, regulatory regions 2,4,5. One drawback of these methods is that the actual impact of 
each variant on regulatory elements is not assessed, as the annotation is based on positional overlap 
only. For example, two SNPs that localize to the same chromatin immunoprecipitation with a 
massively parallel sequencing (ChIP-seq) peak of a transcription factor (TF) 6 might have the same, 
opposing or no functional effects at all. To try to resolve this shortcoming, in silico approaches 
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predicting the degree of disruption of TF binding motifs have been used 7,8. However, our 
understanding of the determinants of TF binding to known sequence motifs is still incomplete, limiting 
the success of such methods. Another post-processing approach to infer functional variants has been 
annotations that correlated SNP genotype with gene expression or DNA methylation data in the form 
of expression and methylation quantitative trait locus (eQTL and meQTL) analyses 9,10. Additional 
methods such as binding QTL (bQTL) studies for TF binding 11 or massively parallel reporter assays 
(MPRAs) now add experimental regulatory information on even a single variant resolution 12-14, yet 
need to be performed in the cell type of interest. While these approaches can indicate regulatory 
effects of associated SNPs, they cannot identify single functional variants within an LD block. 
 
In classical, hypothesis-free GWAS, all variants are treated equally despite it being highly unlikely that 
they are all functionally relevant in every disease-associated tissue of the body. Functional and 
disease relevant variants may show an association strength below the significance threshold, 
increasing the efforts required for identifying such regulatory variants. The integration of functional 
knowledge regarding SNPs into GWAS has the potential to prioritize relevant variants and overcome 
the current hurdle in gaining mechanistic insights into effects of SNPs associated with a specific 
phenotype. 
 
Recent advances in systems genetics that harness the predictive power of deep learning might 
enhance the performance of functional SNP prioritization methods. The deep learning method 
“DeepSEA” uses only DNA sequence information to predict effects on regulatory chromatin features, 
such as histone marks, TF binding, or the presence of open chromatin 15. For this annotation method, 
experimental, publicly available data from the ENCODE project 16 and the Roadmap Epigenomics 
Project 17 for cell type-specific TF binding, histone modifications, and chromatin states were used. 
This type of functional sequence annotation is superior to post-hoc, positional overlap-based 
methods, as it computes allele-specific differences in the effects of variants on regulatory elements 
and thus discerns SNPs with predicted functional impact in a given cell type from those just residing 
within an annotated element by chance. Importantly, the method allows for incorporating cell-type 
specific regulatory effects of variants at baseline as well as under experimentally challenged 
conditions, adding additional critical layers to understanding tissue- and context-specific disease 
mechanisms. This approach was further enhanced to predict tissue-specific gene expression levels 
and to prioritize putative causal variants associated with human traits and diseases 18. Recently, deep 
learning was successfully applied to predict the impact of non-coding mutations in a family with autism 
spectrum disorder 19 and the clinical impact of single human mutations 20. However, in all studies 
published to date, such deep learning-based annotations have only been applied post-hoc to 
association results from classical GWAS. 
  
We present a conceptually new approach fusing classical and functional GWAS. We obtain regulatory 
information on SNPs by generating sets of SNPs mapped to so called “functional units” (FUs) using 
deep learning and then perform multivariate FU-Wide Association Studies (DeepWAS). A FU is 
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defined as the combination of a specific chromatin feature, a cell type, and an experimental condition. 
Regulatory SNPs are then grouped based on their predicted capacity to modulate a FU and are jointly 
subjected to multivariate association with a trait or disease using feature selection with LASSO (L1) 
penalization 21. The rationale of this grouping by FUs stems from the idea that as the majority of our 
chromatin features are TFs (85%, see Supplementary Table 1) and that one TF influences a specific 
cellular function through accumulation of its downstream effects via multiple SNPs on a series of loci 
22. This optimized variant selection improves the power to identify sets of functional SNPs that may 
play a role in the etiology of the disease, and map them directly to a specific context – i.e., cell type, 
transcription factor, stimulation condition. Multiple regression models are relatively new in the field of 
GWAS, but have already shown promising results 23-25. Of note, one of these multi-SNP approaches 
used pre-clustering of LD blocks prior to LASSO modeling 26. 
  
For a proof of concept of this method, we used data from published GWASs of two common diseases, 
multiple sclerosis (MS) 27 and major depressive disorder (MDD) 28, as well as the quantitative trait of 
height 29. The heritability of MS and MDD was estimated to be 64% and 40%, respectively 30,31, 
comparable with other common diseases. The heritable nature of height is estimated to be between 
70-90% 32. GWAS meta-analyses have already identified 180 genetic loci for height 33, 200 for MS 34, 
and 44 independent loci for MDD 35. We compare the results of DeepWAS in smaller samples to the 
results from GWAS meta-analyses of the same phenotypes. This allows to identify disease- or trait-
associated FUs, generating novel supportive evidence for prior knowledge on pathophysiology. We 
also complement deepSNPs with QTL networks and generate novel testable hypotheses of disease 
mechanisms. 
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Results 
Directly integrating regulatory information into genotype-phenotype 
associations (DeepWAS approach) 
In order to integrate regulatory information into the classical GWAS approach, knowledge of 
regulatory information on a single SNP level is required. To retrieve a set of regulatory SNPs with 
effects on cell type-specific chromatin features, we employ DeepSEA variant effect predictions. We 
generated reference and alternative allele sequences of 1,000 bp regions centered around each 
GWAS SNP position (eight million SNPs) and used a pre-trained deep neural network 36 to obtain 
allele-specific probabilities for a genomic feature to manifest in a specific cell type under a given 
experimental condition (a pair of one chromatin feature in one cell type is further called “functional 
unit’’ (FU)). For this study, we used 919 pre-defined FUs (see Supplementary Table 1). For example, 
the FU “p53-baseline-HeLa” was informed by all ChIP-seq peaks of the TF p53 in baseline conditions 
in the HeLa cell line. We then employed the DeepSEA e-value metric that estimates the impact of a 
variant on the functional readout by comparing the allele-specific probabilities per variant to one 
million random SNPs from the 1,000 genomes project 37. Only SNPs with significant e-values (e-
value<5×10-5) were thus selected as likely to be regulatory. This filtering identified 40,000 predicted 
regulatory SNPs, i.e., a SNP with effects in one FU. We next merged all variants that are predicted to 
moderate the same FU into SNP sets. To associate these regulatory SNPs with a disease or trait in a 
multivariate manner, we employ L1-regularized (LASSO) linear regression models including multiple 
SNPs using the stability selection method. From all 919 FU models, we extracted those regulatory 
SNPs that show significant trait association and defined them as deepSNPs (see Methods and 
Figure 1). Moreover, the DeepWAS approach identifies SNP-phenotype associations directly in a cell-
type specific regulatory context.  
To test this approach, we applied DeepWAS to a dataset from an adequately-powered GWAS for MS 
(KKNMS GWAS, 15,283 individuals from two independent MS case-control cohorts 27) and found that 
for 637 out of 919 FU models, associated with at least one variant (see Figure 1B). Most models 
identified one deepSNP per FU while 147 models identified two, three or four deepSNPs to jointly 
moderate a FU. In total 53 unique MS-specific deepSNPs, excluding the region encoding the major 
histocompatibility complex (MHC) on chromosome 6, were identified by DeepWAS. These deepSNPs 
moderate 120 chromatin features in 133 cell lines (see Supplementary Table 2). Note that 16 out of 
the 53 deepSNPs were in pairwise LD with each other (r2≥0.5). 111 MS-specific deepSNPs were 
located in the MHC region. In addition to MS, we analyzed underpowered GWAS datasets for MDD 
(3,627 individuals recruited for recurrent MDD 28,38) and height (3,658 individuals of the population-
based KORA cohort 39). Sixty-one MDD-specific deepSNPs in 237 FUs (Supplementary Figure 1A 
and Supplementary Table 3) and 43 height-specific deepSNPs in 381 FUs (Supplementary Figure 
1B and Supplementary Table 4) were identified in these DeepWAS. 
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Characterization of deepSNPs 
We followed these results up by further characterizing the identified deepSNPs from the three 
independent analyses. DeepSNPs for MS and height were more likely to be located in intronic regions 
(32-33% deepSNPs in first or other introns) while deepSNPs for MDD were more likely to cluster in 
distal intergenic regions (>3 kb=53% vs. >3 kb=36-37% for MS and height, respectively). MS- and 
MDD-specific deepSNPs were never found within coding regions (Figure 2A). DeepSNPs were 
always identified in a cell-type specific manner. We thus interrogated the cell type specificity on the 
level of tissue category, in order to reduce complexity (Figure 2B). Note, that tissue categories were 
influenced by the richness of investigated cell types per category. For example, the tissue group blood 
encompasses 79 cell types, while brain contained only 14 tissues. Overall, more tissue groups were 
identified when the number of identified deepSNPs increased. Interestingly, compared to MS and 
MDD, a lower number of identified deepSNPs for height were relevant in brain tissues. At the same 
time, a larger number of deepSNPs were active in pancreatic tissue. Notably, an association of height 
with pancreatic cancer has previously been shown 40. 
   
As DeepWAS includes only a limited number of histone marks, we next overlapped deepSNPs with 
predicted chromatin states from the 15-state ChromHMM model 41 (Figure 2C). For both DeepWAS 
cell types (ENCODE) and 111 epigenomes, we used top-level tissue categories to overlap deepSNPs 
with chromatin state predictions in the respective matched tissue. We observed tissue and context 
(disease or trait) specific roles of chromatin states. Most of the MS-specific deepSNPs mapped to 
active chromatin states (82%, see Figure 2C). For MDD-specific deepSNPs a larger fraction 
overlapped with repressive marks (43%, see Figure 2C). 
 
To investigate the tissue specificity of the genomic loci around deepSNPs and to extend the number 
of disease-relevant tissues, we further tested if our deepSNPs and their proxies (r2≥0.5) were 
enriched in the loci of tissue-specifically expressed genes by leveraging Fantom CAGE data 42. MS-
specific deepSNPs were significantly enriched in the regions active in different immune cell types, 
height-specific deepSNPs in skeletal muscle cells, pericytes, and also pancreatic carcinoma cell line, 
and MDD-specific deepSNPs in neurocytoma as well as in different brain regions and immune cells 
(p-value≤0.05, see Figure 2D). 
DeepWAS identifies GWAS loci  
To evaluate the convergences of DeepWAS and GWAS, we evaluated how many deepSNPs map to 
cohort-specific results from classical GWAS and to results of larger published meta-analysis of GWAS 
(Figure 3A). In the published GWAS of the KKNMS dataset used in the present study, the MHC 
region as well as variants at 15 loci outside of this region were significantly associated with MS on a 
genome-wide level 27. When comparing KKNMS GWAS and DeepWAS results on a single SNP level, 
eleven of the 53 MS-specific deepSNPs or their LD proxies (r2≥0.5) mapped to eight independent loci 
(CLEC16A, MYO15A, PAGR1, CD58, GFI1, EVI5, and intergenic regions on chromosome 1 and 10). 
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The remaining deepSNPs (n=42) showed an association strength with at least nominal significance in 
the original GWAS with p-values all ≤5.13×10-4, but did not reach genome-wide significance. We next 
overlapped the deepSNPs with results from the GWAS by the International Multiple Sclerosis 
Genetics Consortium (IMSGC 43) that included over 47,000 MS cases and 68,000 controls. Here, a 
total of 12 deepSNPs mapped to nine independent genome-wide significant loci. Eight of these 12 
deepSNPs, corresponding to 8 out of 9 loci, were also genome-wide significant in the KKNMS 
GWAS27.  
 
For MDD, 60 out of the 61 MDD-specific deepSNPs or their proxies (r2≥0.5) reached nominal 
significance in a univariate GWAS from the same cohort (MDDC n=3,627 individuals, no genome-
wide significant association). Five MDD-specific deepSNPs overlapped with the top 10,000 SNPs of 
the recently published largest GWAS for MDD by the PGC 35 (included 135,458 MDD cases and 
344,901 controls; PGC GWAS deepSNP max. p-value ≤ 3.1×10-4), which represents a 2.2 fold 
enrichment (permutation p-value=0.071) over randomly sampled regulatory SNP sets (n=31,929 
regulatory SNPs) and their LD proxies. These five deepSNPs map to five independent loci: ZFPM2-
AS1, SBK2, MTFR1, and two intergenic regions on chromosome 7 (nearby genes: WNT2 and ASZ1) 
and a locus on chromosome 8 (nearby genes: LINC00293 and LOC100287846).  
All of the 43 height-specific deepSNPs reached nominal significance in the classical GWAS in the 
same cohort (KORA cohort n=3,658 individuals, no genome-wide significant association) with a max. 
p-value ≤7.7×10-3. Eight of the 43 height-specific deepSNPs mapped to seven independent genome-
wide significant loci (DIS3L2, ZBTB38, LCORL, PDLIM4, ZNF311, HABP4, and PXMP4) of the latest 
GWAS from the GIANT Consortium, which included over 183,727 individuals 33.  
 
In all the three DeepWAS, this approach identified regulatory SNPs that overlapped not only with 
SNPs associated with the same traits in the cohort-matched GWASs, but also with genome-wide 
significant associations from the larger consortia GWASs for these traits. These associations had not 
survived correction for multiple testing in the underpowered cohort-matched GWAS, but were 
detected using DeepWAS. 
 
Deriving hypotheses on disease-associated mechanisms in MS from 
DeepWAS result 
We next wanted to illustrate how DeepWAS can accelerate the discovery of disease 
mechanisms. Within the DeepWAS results for MS, we identified, for example, the intergenic 
region IL20RA-IL22RA2 on chromosome 6 that includes deepSNP rs62420820 (Figure 3B), 
which was genome-wide significant in the IMSGC GWAS (p-value=9.26×10-36, Figure 3D) 
and nominally significant in the KKNMS GWAS conducted on the MS cohort used for the 
DeepWAS analysis (p-value=1.23×10-5, Figure 3D). In comparison to the published GWAS-
based results, DeepWAS adds the novel and testable hypothesis that the TFs MafF and 
MafK contribute to MS susceptibility. The IMSGC GWAS and deepSNP rs62420820 shows 
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allele-specific TF binding differences for MafF and MafK in the leukemia cell line K562 
(Figure 3C). Of note, additional deepSNPs were identified within the FUs MafK:K562 
(Figure 3B/E: deepSNP rs12768537 on chromosome 10 and Figure 3B/F: deepSNP 
rs137969 on chromosome 22) and MafF:K562 (deepSNP rs12768537), supporting a role of 
these TFs in the etiology of MS.  
 
We also identified deepSNPs that were detected at a genome-wide significance level by both the 
cohort-matched KKNMS GWAS and IMSGC GWAS. This includes deepSNP rs1985372 on 
chromosome 16, located in the CLEC16A locus, previously suggested as a candidate gene for MS 
(the deepSNP rs1985372 was significant in the KKNMS GWAS on the same cohort and is in complete 
LD with the SNP rs2286974 (r2=0.99), which was significant in the IMSGC GWAS 27,43). DeepWAS 
now adds the regulatory information that these SNPs alter TF binding of GABP, GATA-1, GATA-2, 
p300, STAT1, STAT2, STAT5A, and TBLR1, all expressed in K562 cells, and that these TFs play a 
MS-specific role in regulation of CLEC16A. 
 
Regulatory effect of MS-specific deepSNP loci 
Allele-specific effects on chromatin features and TF binding are likely to be reflected by changes in 
DNA methylation and gene expression. To test whether the MS-specific deepSNPs or their proxies 
(r2≥0.5) associate with differences in gene expression and DNA methylation, we used publicly 
available cis-meQTL, cis-eQTL, and eQTM data from multiple resources: 1) The Biobank-Based 
Integrative Omics Study (BIOS) analyzing whole blood (>2000 samples) 44,45, the CommonMind 
Consortium (CMC 46) dorsolateral prefrontal cortex data (DLPFC) (n=603 samples), and GTEx data 47. 
In the largest resource, BIOS, we observed that 36 of the 53 non-MHC, MS-specific deepSNPs were 
significant meQTLs (68%) and 20 significant eQTLs (38%), which represent a 1.7 and 1.9 fold 
enrichment over randomly sampled regulatory SNPs and their assigned LD proxies, respectively 
(permutation p-values≤0.011, see Figure 4A and Supplementary Table 5). We next restricted 
DeepWAS hits to deepSNPs moderating immune cell lines (n=13 deepSNPs, 46 chromatin features, 
4 cell lines and 50 FUs, Supplementary Table 2), given the relevance of this tissue in MS 48. Of this 
subset of 13 immune MS-specific deepSNPs, 62% (n=8 deepSNPs) overlapped with meQTL variants 
(meSNP) and 38% (n=5 deepSNPs) with eQTL variants (eSNP) in BIOS. In their recent study, the 
IMSGC identified significant eQTL effects in naive CD4+ T cells and monocytes for only 18% of their 
significant GWAS loci 49.  When overlapping our immune MS-specific deepSNPs with the same QTL 
datasets, we found 43% (n=23 SNPs) of these deepSNPs to be part of eQTLs in CD4+ T cells and 
38% (n=20 deepSNPs) in monocytes. In addition to publicly available data, we also conducted an 
eQTL analysis using blood gene expression levels from a subset of 319 MS patients of the MS cohort. 
In total, 47% (n=25 deepSNPs) of our MS-specific deepSNPs showed a significant eQTL effect in this 
data (Figure 4A and Supplementary Table 6), of which 14 deepSNPs had previously been identified 
as part of eQTLs in blood. In the GTEx database, we found 42% of these deepSNPs to have a 
significant effect in blood eQTLs (Supplementary Table 8).  
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Taken together, QTL data from various resources support that the DeepWAS of MS identified SNPs in 
transcriptionally relevant regions and emphasize their putative regulatory role in immune function. 
 
Regulatory effect of MDD and height deepSNP loci 
The 61 MDD- and 43 height-specific deepSNPs were also transcriptionally active in the respective 
relevant tissues (see Figure 4A and Supplementary Tables 9-16) and tagged more BIOS eQTLs 
and meQTLs than expected by randomly sampling of regulatory SNPs and assigning their LD proxies 
(MDD: fold enrichment for eQTLs=1.7 and meQTLs=1.5, permutation p-value=0.009 and 0.015, 
respectively; height: fold enrichment for eQTL=1.5 and meQTLs=1.5, permutation p-value=0.068 and 
0.013, respectively, see Methods). Interestingly, in the much larger PGC GWAS only 20% of their 44 
genome-wide significant hits overlapped with BIOS meQTLs 35, while the overlap was 54% for MDD-
specific deepSNPs (Figure 4A). For a subset of both the MDDC and the KORA cohort, methylation 
levels and/or expression levels were measured. We therefore calculated meQTL and eQTL effects 
and found 16% of MDD-specific deepSNPs with significant meQTL effects, 65% of the height-specific 
deepSNPs with meQTL and 33% with eQTL effects (see Figure 4A and Supplementary Tables 
10,14-15).  
 
All data from DeepWAS results with additional QTL information is stored in a searchable graph 
database and accessible at https://github.com/cellmapslab/DeepWAS. 
Disease mechanisms on the level of functional units 
While DeepWAS can be used to predict the phenotype from the genotype, it is also interesting to 
annotate the relationship of FUs to disease or trait. For example, MS is an immune-mediated disorder 
affecting the central nervous system (CNS). Naturally, the CNS is difficult to directly examine as a 
study tissue. DeepWAS might here be used to identify a good proxy study tissue. To interrogate this 
hypothesis, we counted the number of MS-specific deepSNPs of each MS associated FU tissue group 
that overlapped with eSNPs of a GTEx tissue group (Figure 5B and Supplementary Figure 2). The 
MS heatmap in Figure 4B support the hypothesis that a proxy tissue can be identified and suggests 
that blood deepSNPs are surrogates for brain tissues and other tissues, especially for the thyroid.  
 
Moreover, DeepWAS results can be used to identify single SNPs as key regulators, i.e., those SNPs 
with effects on multiple chromatin features. DeepWAS identified, for example, the intergenic deepSNP 
rs175714 on chromosome 14 as a key regulator for MS (Figure 5A-B). It affects the binding of 
multiple chromatin features at the same time (n=29) in 116 cell types (Figure 5A-B). One of these 
chromatin features is the TF MAZ. MAZ itself is one of the top-associated loci of the KKNMS GWAS 
(tag SNP rs34286592 on chromosome 16, p-value=4.58×10-10), but no significant transcriptional effect 
was previously identified in a post-hoc analysis of the GWAS 27. Interestingly, the MS-specific 
deepSNP rs175714, together with the MS-specific deepSNP rs11000015 on chromosome 10, had a 
significant effect on the binding of MAZ and they were jointly associated with MS disease status. The 
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deepSNP rs11000015 is correlated with expression levels of the Prosaposin (PSAP) gene in multiple 
tissues, whole blood gene expression levels of PSAP are shown in Figure 5C. 
 
Another example is the TF MEF2C in the analysis of MDD, where DeepWAS identified the intergenic 
SNP rs7839671 on chromosome 8 as one of the key regulators for MDD (see Supplementary Figure 
3). MEF2C is an important risk gene for MDD and the MEF2C gene itself is one of top-associated loci 
of the PGC GWAS for MDD 35 (MEF2C, chr5: 87.443-88.244 Mb, p= 7.9×10-11, Supplementary 
Figure 3). SNP rs7839671 and its proxies are associated with differences in mRNA expression of 
SPIDR and MCM4 and show meQTLs with an intergenic region (for more details, see 
Supplementary Figure 3).  
QTL network analyses 
In-depth investigation of the wealth of additional regulatory capacities of deepSNPs were carried out 
by generating QTL-networks that combine all pairwise links of meQTL (SNP-CpG), eQTL (SNP-gene), 
eQTM (CpG-gene), and deepSNP-FU information. QTL network analyses helped us to identify the 
SNPs that showed joint effects on epigenetic and transcriptomic levels, i.e., deepSNP = eSNP = 
meSNP where the deepSNP harbors an eQTM. The resulting networks are called three-way QTL 
interaction networks. Three MS-specific deepSNPs on chromosome 17, rs2273030, rs4925172 (both 
in complete LD with each other r2=1), and rs7207666 (r2=0.7) are located in the SHMT1 locus, a 
candidate gene for MS 27,49 (Supplementary Figure 4A). The genetic variants and SHMT1 are 
connected via eQTL, meQTL, and eQTM relations (Supplementary Figure 4B). In comparison to the 
previously published findings on the locus, DeepWAS informs that the TF Yin Yang 1 (YY1), 
expressed in multiple cell lines, may lead to a downregulation of SHMT1 gene expression and 
hypermethylation of cg25492364 and cg26763362, thus connecting the disease associated SNPs with 
specific regulatory functions.  
 
Moreover, a three-way QTL interaction network analysis identified the height-specific deepSNP 
rs7146599 on chromosome 14 to affect a cascade of eight chromatin features in eleven cell lines (see 
Supplementary Figure 5A-B). The network also included rs2871960 on chromosome 3, linked to the 
ZBTB38 locus and correlated with multiple CpG sites. ZBTB38 has been previously shown to play an 
important regulatory role in height 50.  
 
Thee-way QTL interaction network analysis identified the MDD-specific deepSNP rs163105 on 
chromosome 5 to alter the expression of SKIV2L2 (also known as MTR4). This gene has already 
been shown to be differentially expressed between depressed women and controls 51 (see 
Supplementary Figure 6). Furthermore, SKIV2L2 has been implicated in the stress response and 
neurodegeneration through the nuclear exosome-targeting (NEXT) complex 52.  
 
In summary, DeepWAS allows the direct identification of putative master regulators, TFs and 
chromatin features for a subsequent in-depth analysis of genetic association signals.
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Discussion 
In classical GWASs, all SNPs are tested independently from each other on a genome-wide scale, 
thereby implicitly assuming that any SNP can moderate the function of any cell state at any time. It is 
now clear that disease associations, especially regarding common disorders, are driven by SNPs 
altering the function of regulatory elements. Hence, it is likely that testing all SNPs in GWAS is not 
necessary but rather we should use functional annotation to help prioritize putative risk variants 17. So 
far, several post-hoc functional annotations of GWAS results have been reported 53-55. In this 
manuscript, we present DeepWAS, a novel analysis tool for genetic associations that fuses GWAS 
and functional annotation into one single step (Figure 1). We employ the powerful deep learning 
based method DeepSEA to predict regulatory effects of chromatin features in various cell types on a 
single SNP level 36. In addition, we implement multi-SNP regression models with L1 regularization to 
identify so-called deepSNPs. The SNPs of one FU are only selected when they are jointly associated 
with the disease or trait. To the best of our knowledge, this study is the first to combine deep learning-
based predictors with multivariate models. By applying DeepWAS to three datasets, we show that this 
method allows direct fine-mapping of GWAS associations at a single base resolution as well as direct 
functional annotation of the association signal to both chromatin features and cell types, generating 
novel mechanistic hypotheses. We also demonstrate that DeepWAS, by pre-selecting functionally 
relevant SNPs and integrating multivariate statistics, might increase power to detect true positive 
signals. 
 
We applied DeepWAS on a well-powered GWAS dataset for MS (n=15,283 individuals), but also to 
underpowered GWAS data for MDD (n=3,627 individuals) and height (n=3,658 individuals). In all 
three phenotypes, many SNPs in many genes contribute to genetic variation in the population and the 
effect size of each SNP was found to be small 56. Therefore, large sample sizes are needed to 
discover additional risk variants. We identified 35 putative new candidate MS risk SNPs outside of the 
MHC region that did not reach genome-wide significance in GWAS (in total: 53 non-MHC, MS-specific 
deepSNPs). For MDD, DeepWAS prioritized 56 new putative risk variants (in total: 61 MDD-specific 
deepSNPs) and for height 35 new risk variants (in total: 43 height-specific deepSNPs), even though 
the classical GWAS approach for MDD and height did not yield genome-wide significant results. 
Importantly, when comparing our deepSNPs identified in these smaller cohort-matched GWASs to 
large consortia GWASs of the same phenotype, DeepWAS was able to detect SNPs that reached 
genome-wide significance in these large consortia GWASs but not in GWAS of the same sample 
(Figure 3). Importantly, all deepSNPs were associated at least with nominal significance in cohort-
matched GWAS, with a subset of deepSNPs reaching genome-wide significance. Interestingly, when 
comparing our deepSNPs to the larger consortia GWASs, DeepWAS detected SNPs that reached 
genome-wide significance in these GWASs but not in the smaller-scale GWAS on the individual 
cohorts (Figure 3). For example, 23% of the 53 MS-specific deepSNPs were previously identified in 
the ISMGC MS GWAS including more than 135,000 individuals (>47,000 MS cases). One-third of 
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these deepSNPs were not detected in the univariate KKNMS GWAS using the same cohorts as in 
DeepWAS (n>15,000 individuals). The increased power of DeepWAS is underlined by the observation 
that when, for example, all regulatory MS SNPs (n=36,409 SNPs), without grouping to FUs, were 
used as input to a single LASSO regression model with stability selection, only 19 SNPs showed a 
significant association with MS, of which four mapped outside the MHC region. This is in contrast to 
the 164 MS-specific deepSNPs identified using DeepWAS, of which 53 were outside of the MHC 
region. Notably, these 36,409 SNPs reside in only 25,000 independent loci, which is also reflected by 
the fact that 16 out of 53 MS deepSNPs are not independent from each other. The regulatory 
genotypes have, thus, little correlation and are therefore suitable to be subjected to a L1 penalization. 
In summary, DeepWAS can increase the power to detect associations of a phenotype with regulatory 
variants, with genome-wide significant consortia GWAS variants detected using DeepWAS in smaller 
samples in which they only showed sub-threshold signals using classical GWAS. As outlined below, 
functional analyses of identified deepSNPs suggest that the additional signals discovered using 
DeepWAS but not using classical GWAS reside within known, disease-relevant functional pathways 
and thus likely constitute true-positive associations. 
 
Particularly for non-coding regulatory SNPs, DeepWAS has an advantage over GWAS followed by 
post-hoc annotation and allows to identify transcriptionally relevant regions in the disease context 
(Figures 2-5). In fact, in all three DeepWAS, deepSNPs were identified in cell types and enhancers 
previously shown to be relevant for the tested phenotype. For example, 47% of the MS-specific 
deepSNPs (n=35) affect the binding of chromatin features in hematopoetic tissue, and another 30% 
affect chromatin features in brain tissue or spinal cord (n=16; Figure 2B). These findings revealed 
that the genetic disease risk is driven by altered binding of chromatin features mainly in these two 
tissues.  
DeepWAS results also pointed towards convergent regulatory mechanisms of specific TFs in both MS 
and MDD. For both disorders, DeepWAS identified a set of SNPs modulating binding of a TF that was 
found to be associated with the disorders in GWAS. This suggests that SNPs associated with the 
gene encoding the TF and SNPs altering its binding to target transcripts jointly affect the phenotype. 
The gene MAZ on chromosome 16, for example, has been previously identified as a genome-wide 
significant GWAS locus for MS 27. DeepWAS identified several deepSNPs that include the TF MAZ in 
a FU (Figure 5). DeepSNP rs11000015 on chromosome 10 and deepSNP rs175714 on chromosome 
14 alter MAZ binding. Supporting evidence for the importance of deepSNP rs11000015 as a risk 
factor for MS was provided by it being a multi-tissue GTEx eQTL involving PSAP. PSAP codes for 
prosaposin, a precursor of several small nonenzymatic glycoproteins termed sphingolipid activator 
proteins that assist in the lysosomal hydrolysis of sphingolipids 57. Sphingolipids are the main 
components of nervous tissue, and have been previously linked to MS 58. As a second example, we 
identified MDD-specific deepSNPs altering the binding of TF MEF2C (Supplementary Figure 3). 
SNPs in the locus encoding MEF2C are the top signal in the latest meta-analysis for major depression 
35. The MEF2 TF family has been reported to play a major role in synaptic plasticity, which is thought 
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to be disturbed in MDD, especially in the context of stress. Chen and colleagues 59 identified the TF 
MEF2 as a master regulator of developmental metaplasticity, which is important for guiding 
developmental structural and functional neuronal plasticity. Additional evidence was found by Barbosa 
et al. 60, relating MEF2 to activity-dependent dendritic spine growth and suggesting that this TF may 
suppress memory formation. 
To support the validity of the predicted regulatory effects of our DeepWAS associations, we provided 
multiple lines of evidence that deepSNPs and their surrounding loci are indeed functionally active in 
their respective tissue. We chose to prioritize DeepWAS results based on additional regulatory impact 
of DNA methylation and gene expression as shown by their meQTL and eQTL effects. DeepSEA 
together with eQTL data, has been previously applied to prioritize disease-associated variants 61. We 
observed that 68% of MS-specific deepSNPs are meQTLs and 38% eQTLs in the largest QTL 
resource, BIOS. When using only random sets of regulatory SNPs with no disease association, no 
such overlap was found. For all investigated phenotypes, we observed a significant overlap between 
deepSNPs and meQTL SNPs (Figure 4, fold enrichment ≥1.5 and permutation p-value over 1,000 
random sets ≤ 0.015. For MDD- and MS-specific deepSNPs we found a significant overlap with eQTL 
SNPs (Figure 4, fold enrichment ≥1.5 and permutation p-value over 1,000 random sets ≤ 0.011). 
Moreover, as MS is a disorder developing in the peripheral immune system, we investigated if our 
deepSNPs alter the expression of CD4+ T cells or influence the expression in monocytes, and found 
twice as many eQTL effects for deepSNPs as described in the published IMSGC GWAS for MS (43% 
in CD4+ T cells and 38% in monocytes found using DeepWAS vs. 18% in both cell types in the 
IMSGC GWAS). Using expression profiles from GTEx, we found more MS-specific deepSNPs for 
blood eQTL SNPs than in brain-related eQTL SNPs (42% vs.11%). This supports the theory that MS 
is most likely initially triggered by perturbation of immune responses, but that also the functional 
responses of brain cells are altered and may have a role in targeting an autoimmune process to the 
CNS. 
 
Finally, we explored whether generating QTL interaction networks of our deepSNPs and extracting 
the SNPs with an impact on methylation and expression, which also coincidently an eQTM, can help 
identify likely functional risk mechanisms. We identified deepSNPs in the SHMT1 gene, a published 
MS GWAS locus [27,28], where DeepWAS QLT network analysis pinpoints the TF Ying Yang 1 
(YY1), expressed in multiple cell lines including immune related cells, as a potential novel risk factor 
(Supplementary Figure 4). YY1 is a ubiquitously expressed TF shown to be essential for B cell 
development 62 and serves as master regulator of T cell exhaustion 63. Such dysregulation of immune 
related cells has been shown to promote MS progression 64,65. Additional SNP-protein association 
studies (pQTLs) 66 that show how the deepSNP rs2273030 alter YY1 protein abundances could be 
extended to develop clinical applications in the context of MS. 
 
DeepWAS is mostly limited by the comprehensiveness of regulatory element catalogues like 
ENCODE and Roadmap. ENCODE lacks, for example, information for a number of relevant disease-
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specific stimulation conditions as well as disease-related tissues. We have previously reported on the 
importance of testing SNPs in stimulated conditions, and shown that glucocorticoid response 
moderating SNPs only become apparent in the stimulation condition and are not overlapping with 
baseline eQTLs 67. Of note, the glucocorticoid receptor itself is central for the stress response and has 
been previously implicated in the pathogenesis of MDD 67,68. In addition, data from cell lines or bulk 
tissues will miss variants with effects only specific cell types as well as cell type specific effects 
dependent on the systemic, developmental and/or tissue context. It is therefore important to be able to 
retrain the DeepSEA neural network with additional publicly available chromatin features and as well 
as newly generated experimental data. This will be possible using the DeepWAS pipeline publicly 
available at https://github.com/cellmapslab/DeepWAS.  
 
In summary, our results indicate that DeepWAS, a method combining deep learning based functional 
SNP annotation and considering a possible multivariate effect of SNPs to moderate a trait or disease, 
is a powerful tool to uncover disease mechanisms for common disorders and traits. It also allows 
direct identification of regulatory SNPs by having a single base resolution and not being limited by the 
LD structure of the locus, since our regulatory SNPs are mostly independent and we jointly analyze 
regulatory SNPs only if they are predicted to modulate the same FU (see Methods). With ever 
increasing amounts of available functional data, the DeepWAS approach will become even more 
valuable and allow integration of both publicly as well as unpublished data generated by individual 
labs. DeepWAS is a versatile, publicly available tool that can be applied to any GWAS dataset in 
conjunction with the code available for DeepSEA. While we tested DeepWAS in small and medium 
size samples, and observed a potential increase in power in detecting phenotype-relevant functional 
SNPs, applying this method to very large datasets will be even more informative.
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Figures  
 
Figure 1: Workflow of DeepWAS. A) A deep-learning based framework predicts combined binding 
probabilities for chromatin features, cell lines, and treatments, called functional units (FU) for 1,000 bp 
centered around a SNP. FUs are selected for a potential functional role of a variant using a cutoff for 
functional scores. This process is repeated for all genotyped variants. The genotype-phenotype 
association is analyzed for each FU using LASSO regression with stability selection. Unlike GWAS, 
DeepWAS implicates a regulatory mechanism underlying the phenotype of interest with information 
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on relevant cell lines and TFs. B) DeepWAS was applied to 36,409 regulatory SNPs that were 
retained after filtering for allele-specific effects in any given FU. These SNPs were tested for an 
association with multiple sclerosis (MS). The heatmap shows the number of selected chromatin 
features vs. cell lines. Chromatin features are limited to be present in at least two distinct cell lines. 
Missing values, represented in white, show FUs for which no data were available. 
 
Figure 2: Functional characterization of DeepWAS hits. A) Annotation of the genomic regions in 
which deepSNPs are located: 63-87% of the genomic positions of deepSNPs overlapped with non-
coding DNA elements. Seventeen of 53 MS-specific (32%), 14 of 43 height-specific (33%) and 8 of 61 
MDD-specific (13%) deepSNPs mapped to introns (first and other introns). Over a half of the MDD-
specific deepSNPs (53%) resided in distal intergenic regions (>3 kb). None of the MS- and MDD- 
specific deepSNPs were located in exons. B) Bar plots for each phenotype showing the number of 
unique deepSNPs annotated to a top-level tissue category (ENCODE). C) Overlap of MS-, MDD-, and 
height-specific deepSNPs with ChromHMM states from Roadmap epigenomes based on top-level 
tissue group matching. Most of our MS- and height-specific deepSNPs mapped to predicted active 
chromatin states (82-86%), whereas nearly half of MDD-specific deepSNPs mapped to inactive 
chromatin states (43%). D) Tissue enrichment with FANTOM gene expression data. The top 15 
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Figure 3: Comparison of DeepWAS vs. GWAS results. A) Bar plot of the overlap of cohort-
matched GWAS and consortia GWAS SNPs with deepSNPs. g.-w. s=genome-wide significant. B) 
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rs62420820 in the K562 cell line, a genome-wide significant signal in the IMSGC MS GWAS, but sub-
threshold in the cohort-specific KKNMS GWAS. Edges represent the association relation of 
deepSNPs, chromatin features with or without treatment, cell lines, and top-level tissue group. C) Bar 
plots showing the predicted DeepSEA probabilities for deepSNP sequences carrying the alternative 
and reference allele group by their FU. D-F) Locus-specific Manhattan plots of the MS-specific 
deepSNPs rs62420820, rs12768537, and rs137969, based on classical GWAS. Plots were produced 
using LocusZoom with EUR samples of the 1,000 genomes November 2014 reference panel on the 
hg19 build 69. Dots represent KKNMS GWAS p-values and the diamond shows the IMSGC GWAS 
signal p-value. Color of the dots indicates LD with the lead variant = deepSNP (magenta), grey dots 
have LD r2 missing.  
 
Figure 4: Context-related regulatory capacity of deepSNPs. A) Heatmap showing the percentage 
of overlap of MS-, MDD-, and height-specific deepSNPs or their proxies (r2≥0.5) with cis-meQTL and 
cis-eQTL data from multiple resources, see also Supplementary Tables 5-16. B). Heatmap depicting 
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Figure 5. QTL network. A) Network showing one of the putative key regulators for MS, deepSNP 
rs175714 on chromosome 14. DeepSNP rs175714 is associated with differential TF binding of the TF 
MAZ, one of the top-associated loci in the KKNMS GWAS, where no significant transcriptional effect 
could be identified in the post-hoc analysis. Edges represent the associations between deepSNPs 
and chromatin features with or without treatment, cell lines, top-level tissue group, CpGs, and genes 
through dummy nodes identified either using DeepWAS or QTLs. Dummy nodes are used for 
preserving all entities of deepSNP and QTL associations. Edges highlighted in red show the 
DeepWAS results for MAZ, in yellow show the eQTL connections illustrated in B, and shades refer to 
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downstream QTL results shown in B. B) Box plot of GTEx whole blood eQTL data showing the 
relationship between PSAP gene expression and deepSNP rs11000015 genotype. C-D) Chromatin 
feature probabilities for the significant FU of the deepSNP sequences carrying the reference 
(black) and alternative (gray) allele. 
Supplementary Figures 
Supplementary Figure 1: The heatmaps showing the number of selected chromatin features vs. cell 
line for A) MDD and B) height. Chromatin features are limited to be at least present in two distinct cell 
lines.  
 
Supplementary Figure 2: Heatmaps depicting GTEx tissue groups and DeepWAS top-level tissue 
category overlap with the A) MDD- and B) height- specific deepSNPs. 
 
Supplementary Figure 3: A) Graph-based QTL Network visualization of the DeepWAS results 
involving the TF MEF2C, which itself is one of the top associated PGC GWAS loci. Two deepSNPs 
are jointly associated with MDD and belong the same FU: MEF2C:GM12878. Edges represent the 
association relation of deepSNPs, chromatin features with or without treatment, cell lines, top-level 
tissue group, CpGs, and genes. Edges of the FU MEF2C:GM12878 are colored in red. Circular 
shades mark the corresponding genes or CpGs with are plotted in B and C. B) Box plot of GTEx 
frontal cortex eQTL data showing relationship between SPIDR gene expression and deepSNP 
rs7839671. C) Boxplot of recMDD meQTL data illustrating relationship between cg01650371 
methylation and rs10099827 genotype in recMDD samples. Variant rs10099827 is a proxy of 
deepSNP rs7839671 (r2=0.8). DeepSNP rs7839671 exhibits a meQTL effect on the same CpG and 
was excluded from the original meQTL analysis, as it is 571 kb away from the CpG site (meQTL 
distance cutoff≤250 kb). 
 
Supplementary Figure 4: A) Locus-specific Manhattan plot of the deepSNP rs2273030 that is a sub-
threshold GWAS SNP for MS. The plot is produced using LocusZoom with EUR samples of the 1,000 
genomes November 2014 reference panel on the hg19 build 69. Dots represent GWAS p-values and 
the color of dots indicates LD with the lead variant, grey dots have LD r2 missing. B) MS-specific 
three-way QTL interaction network generated by using a graph database and highlighting only the 
deepSNPs with eQTL and meQTL effects that also harbor an eQTM. Edges represent the association 
relation of deepSNPs, chromatin features with or without treatment, cell lines, top-level tissue group, 
CpGs, and genes.   
 
Supplementary Figure 5: A) Height-specific three-way QTL interaction network highlighting 
deepSNP rs7146599 on chromosome 14 as one of the moderators of height in eleven cell lines. It 
affects a cascade of chromatin features (n=8) and shows meQTL and eQTL effects that, at the same 
time, harbor an eQTM. The CpG site and the deepSNP thus affect the transcriptional level of the 
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same genes. In addition, the network includes rs2871960 on chromosome 3, linked to the ZBTB38 
locus and correlated with multiple CpG sites. Edges represent the association relation of deepSNPs, 
chromatin features with or without treatment, cell lines, top-level tissue group, CpGs, and genes. 
B) Heatmap illustrating the deepSNPs affecting the binding of more than four chromatin features. 
 
Supplementary Figure 6: MDD-specific three-way QTL interaction network generated by using a 
graph database and highlighting only the deepSNPs with eQTL and meQTL effects that also harbor 
an eQTM. It shows that the MDD-specific deepSNPs rs163105 on chromosome 5 changes the 
expression of SKIV2L2 (also known as MTR4). Edges represent the association relation of 
deepSNPs, chromatin features with or without treatment, cell lines, top-level tissue group, CpGs, and 
genes. 
 
Supplementary Figure 7: Lasso Stability selection results for FU: MEF2C-GM12878: the y-axis 
indicates number of boosting iterations, the x-axis indicates the stability selection probability, and the 
horizontal line correspond the 0.7 probability threshold. 
Supplementary Tables 
Supplementary Table 1: List of all functional units 
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Methods 
Clinical Samples 
Major depressive disorder cohorts (MDDC) 
Two MDD cohorts, recMDD and BoMa, were analyzed. The recMDD cohort consists of 1,774 
Caucasian individuals recruited at the Max-Planck Institute of Psychiatry (MPIP) in Munich, Germany 
and two satellite hospitals in the Munich metropolitan area (BKH Augsburg and Klinikum Ingolstadt): 
756 controls (581 women, 275 men) and 879 cases diagnosed with recurrent major depression (585 
women, 294 men). Please see Muglia et al. 28 for more details on sample recruitment and 
characterization. The BoMa cohort consists of 1,889 Caucasian individuals: 1,292 controls (656 men, 
636 women), 597 (212 men, 385 women) of which had a depressive disorder. Recruitment strategies 
and further characterization have been described previously 70. 
Multiple sclerosis cohorts (KKNMS) 
Two MS cohorts, referred to as DE1 and DE2, were analyzed. Both data sets included patients 
diagnosed with either MS or the prodromal clinically isolated syndrome. DE1 consists of 3,934 cases 
and DE2 consists of 954 cases; for more details see Andlauer et al. 27. Controls for these cohorts 
were obtained from several cohorts across Germany: KORA39, HNR 71, SHIP 72, DOGS 73, FoCus 74, 
PopGen 75, recMDD 28 , and MARS 76 ; for more details see Andlauer et al. 27. 
Population-based cohort (KORA) 
The study population consisted of participants from the KORA (Kooperative Gesundheitsforschung in 
der Region Augsburg) study 39, which has been collecting clinical and genetic data from the general 
population in the region of Augsburg, Germany for more than 20 years. Here, the independent cohorts 
S3 and S4, including their follow-ups (F3 and F4), were analyzed. 
Genotype data and imputation 
Data generation 
Genotype data was generated for each cohort individually. Details on the methods used can be found 
in the individual papers (recMDD 28, BoMa 70, KKNMS 27, and KORA 39). 
Quality control and imputation 
Quality control (QC) of KKNMS genotype data and imputation have been previously described 27 and 
the same pipeline was applied for KORA and recMDD genotype data. The QC was conducted in 
PLINK 1.90b3s or higher 77 for each cohort separately. QC steps on samples for KKNMS, KORA, and 
recMDD included removal of individuals with missing rate>2%, cryptic relatives (PI-HAT>0.0125), and 
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genetic outliers (distance in first eight MDS components from mean >4 SD). QC steps on variants 
included removal of variants with a call rate<2%, MAF<1%, and HWE test p-value≤10-6. Furthermore, 
variants on non-autosomal chromosomes were excluded. QC steps for BoMa included removal of 
variants with call rate <5% (before sample removal), individuals with missing rate >2%, autosomal 
heterozygosity deviation (|Fhet|< 0.2), variants with call rate <5% (after sample removal), difference in 
variant missingness between cases and controls <2%, variants with MAF<1%, and variants with HWE 
test p-value≤10-6 in controls or p-value≤10-10 in cases. All non-autosomal chromosomes were 
excluded. 
Imputation was also performed separately for each cohort using IMPUTE2 78, following phasing in 
SHAPEIT 79, with the 1,000 genomes phase I reference panel (released in June 2014, ALL samples). 
QC of imputed probabilities was conducted in QCTOOL 1.4 (http://www.well.ox.ac.uk/~gav/qctool/). 
Imputed SNPs were excluded if MAF<1%, HWE test p-values ≤10-6 and the INFO metric <0.8. SNP 
coordinates are given according to hg19. 
Statistical analyses of genotype data (GWAS) 
The GWAS for MDD was separately conducted on the two MDD cohorts, recMDD and BoMa. The 
GWAS for height was carried out using the population-based cohorts of KORA S3 and S4. PLINK 
1.90b3s was used for these GWAS 80.  Multidimensional scaling (MDS) was separately conducted on 
each GWAS cohort. For height the number of consecutive MDS components cumulatively explaining 
at least 80% of the genetic variance were selected as covariates (n=8) and for MDD the number of 
MDS components was selected based on Cattell's scree test (n=3). Sex, age, and MDS components 
were used as covariates in logistic or linear regression. Data sets were combined using a fixed-effects 
meta analysis in METAL 81.  The same covariates were retained for analysis with the DeepWAS 
method. For MS, the published GWAS results were used. 
Prediction of regulatory effects using DeepSEA 
We employed DeepSEA 36 to determine the SNPs that potentially play an important role in human 
traits or diseases by acting through the alteration of regulatory elements. All the 919 DeepSEA 
chromatin features 36 representing regulatory information derived from the profiles of the ENCODE 
project 16 were considered as FUs. These units cover combinations of 201 different experimental 
annotations of epigenetically relevant information. This data includes 690 TF binding profiles for 160 
different TFs, 125 DNase I hypersensitive site (DHS) profiles, and 104 histone mark profiles across 31 
cell lines and 17 treatment conditions. The pretrained DeepSEA network (v0.94) was downloaded 
from http://deepsea.princeton.edu/help/ and the predictions and corresponding significance values of 
the regulatory effects, so-called e-values, of the set of all SNPs from three datasets were generated 
using a NVIDIA GeForce GTX TITAN X GPU (Maxwell). Significance was assessed by the method 
proposed by Zhou & Troyanskaya, which uses one million random SNPs from the 1,000 genomes 
project 37 as a background distribution to calculate e-values for each FU, by assessing the proportion 
of random variants with a bigger effect than that of observed variants. We applied an e-value cutoff of 
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5×10-5, to only take the SNPs associated with at least one FU into consideration (e.g., rs1035271 in 
GM12878:MEF2C). We refer to this set of SNPs as having a predicted regulatory effect. 
DeepWAS 
Penalized regression models 
Compared to the classical GWAS approaches where the trait of interest is regressed separately on 
each SNP, regularized regression approaches provide an alternative way to handle high dimensional 
data and to identify SNPs associated with the trait of interest using variable selection 23. Here we 
utilized L1-regularized logistic and linear regression (LASSO) with stability selection for variable 
selection implemented in the “stabs” R package 82.  We decided to use LASSO regression instead of 
Elastic Net, as our regulatory SNPs were lowly correlated, i.e., of the 36,409 SNPs that were 
predicted to be regulatory for the imputed, high quality MS SNP set, 26,155  (72%) were uncorrelated 
(r2<0.2, window size of 50 SNPs, and a shift parameter of 5), with a mean r2 per FU ranging from 
0.001 to 0.3. Furthermore, the fine-tuning of the Elastic Net meta-parameter L2 (alpha) is more 
difficult and time-consuming (for more details please see 23). Therefore, for each of 919 FUs, we fitted 
LASSO models via stability selection procedure in order to estimate stable statistical associations 
between the disease or trait status (binary for MS and MDD, continuous for height) and SNPs in the 
context of a specific cell line. Linear models fitted to datasets with a continuous response are 
described as follows: 
𝑦! = 𝛽!"#,!,!𝑋!,! !∈!! + 𝛽!"#,!𝑠𝑒𝑥! + 𝛽!"#,!𝑎𝑔𝑒!  + 𝛽!"!!"#,!𝑐𝑜ℎ𝑜𝑟𝑡! + (𝛽!"#,!,!𝑚𝑑𝑠!,!)
!
!!! + 𝛽!! + 𝜖 
In each LASSO model, only the SNPs that significantly affect the binding of a specific chromatin 
feature in a specific cell line were included. This is represented in the equation by the summation over 
the elements of 𝑆!, which represents the set of SNPs that have an impact on FU 𝑘. Subscript 𝑘 is 
used as a model index, which denotes a different model for each FU. We refer to the genotype matrix 
(e.g., 15,283 x 36,409 for the KKNMS dataset) as 𝑋 where the rows are individuals (subscript 𝑖) and 
columns are SNPs (subscript 𝑗). Genotype in the 𝑋 matrix is encoded using the dosage representation 
of each SNP in an additive model such that the final encoding of a SNP is 𝑋!" = 2×𝑃(𝐴𝐴!") + 𝑃(𝐴𝑎!") 
where 𝑃(𝐴𝐴!") and 𝑃(𝐴𝑎!") are probabilities for being homozygous for the minor allele and 
heterozygous for individual 𝑖 and SNP 𝑗. 𝑋!" is therefore a continuous value between 0 and 2. In 
addition to the SNP predictors, we used sex (binary), age (continuous), cohort dummy index, and 
MDS components (continuous) as covariates. 
The model parameters (𝛽) of the linear regression for continuous phenotype are optimized with L1 
regularization, where the 𝜆 parameter represents the strength of the regularization. We fitted L1-
regularized logistic and linear regression models (LASSO) using glmnet and stabs R packages 83,84. 
The regularization parameter 𝜆 is determined within the stability selection procedure, based on a 
provided probability cutoff and per-family error rate (PFER) values 85. Note that, unlike family-wise 
error rate and false discovery rate, which define a probability and an expected proportion, 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/069096doi: bioRxiv preprint first posted online Aug. 11, 2016; 
 
 
Arloth J, Eraslan G et al. 
 
 24  
respectively, PFER defines the expected number of false positives and hence can be above 1.0. In 
total, n=100 subsample replicates were used for each model fit with a subsample size of ⌊n/2⌋. The 
probability cutoff represents how frequently a variable must be selected in LASSO models fitted to 
these replicates in order to be called a deepSNP. For more details of the relationship between the 𝜆 
parameter, probability cutoff, and PFER values please see 86. 
 
DeepWAS application 
DeepWAS was conducted on the KKNMS dataset for MS, on the MDDC dataset for MDD, and on the 
KORA dataset for height. Sex, age, cohort membership, and significant MDS components were used 
as covariates in DeepWAS. A selection probability >0.7 and a PFER of 1.0 were used to identify 
significant trait associations (deepSNPs). 
Functional annotation of deepSNPs 
DeepWAS (Encode) tissue category  
Encode cell type information was download from https://genome.ucsc.edu/encode/cellTypes.html and 
tissue categories were extracted from the column „tissue“. 
Roadmap cis-regulatory elements (ChromHMM) 
Cis-regulatory elements identified by the Roadmap Epigenomics Project 87 were downloaded as 
segmentation files of core 15-state ChromHMM model for 111 epigenomes  from the Roadmap 
epigenomics web portal 
(http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/j
ointModel/final/all.mnemonics.bedFiles.tgz) in BED format. ChromHMM used five core marks 
(H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3) from each of the 111 reference 
epigenomes and learned a set 15-chromatin state definitions per genomic segment. We overlapped 
the DeepWAS SNPs with those chromatin states based on the exact genomic position. All roadmap 
epigenomes were grouped into broader tissue groups, which were used for mapping between 
DeepWAS and ChromHMM results. 
Genomic region annotation 
DeepWAS SNPs were overlapped with genomic annotation from UCSC for the hg19 genome build 
using “TxDb.Hsapiens.UCSC.hg19.knownGene” and “ChIPseeker” R packages 88,89. 
Tissue enrichment with SNPsea and FANTOM5 CAGE data 
SNPsea version 1.0.3 90 was downloaded from https://github.com/slowkow/snpsea/. Tissue 
enrichment was performed with the command line interface of SNPsea. All data and annotation files 
were the default ones provided by SNPsea (tissue-specific gene expression from ~400 cell types), 
namely the FANTOM2014.gct.gz gene expression file was used with default NCBIgenes2013.bed.gz, 
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TGP2011.bed.gz, Lango2010.txt.gz values for “gene-intervals”, “snp-intervals”, and “null-snps” 
options, respectively.  
DNA methylation data 
For a subset of the recMDD cohort (n=166 MDD cases), genomic DNA was extracted from whole 
blood using the Gentra Puregene Blood Kit (QIAGEN). DNA quality and quantity of both was 
assessed with the NanoDrop 2000 Spectrophotometer (Thermo Scientific) and Quant-iT Picogreen 
(Invitrogen). Genomic DNA was bisulfite converted using the Zymo EZ-96 DNA Methylation Kit (Zymo 
Research) and DNA methylation levels were assessed for >480,000 CpG sites using the Illumina 
HumanMethylation450 BeadChips. Hybridization and processing were performed according to the 
manufacturer’s instructions. QC of methylation data, including intensity read outs, filtering (detection 
p-value > 0.01 in at least 75% of the samples), cellular composition estimation according to 91, as well 
as beta calculation were done using the minfi Bioconductor R package v1.18.2 92. Filtered beta values 
were reduced by eliminating any CpG sites on sex chromosomes, as well as probes found to have 
SNPs at the CpG site itself or in the single-base extension site with a MAF ≥1% in the 1,000 genomes 
project EUR population and/or non-specific binding probes according to 93. Additionally, we performed 
a re-alignment of the array probe sequences using Bismark 94. This yielded a total of around 425,000 
CpG sites for further analysis. The data were then normalized using functional normalization 95. 
Technical batch effects were identified by inspecting the association of the first principal components 
of the methylation levels with plate and plate position as technical batches. The data were then 
adjusted using ComBat 96. CpG coordinates are given according to hg19. 
 
DNA methylation data was available for a subset of the KORA study (n= 1,802 F4 individuals). DNA 
methylation was measured with the Illumina HumanMethylation450K BeadChips. Sample preparation 
and measurement have been described previously 97. Intensity values were extracted from the idat 
files using the Bioconductor R package minfi, with subsequent background correction performed with 
lumi 98.  Probes with a detection p-value > 0.01 or summarized by less than 3 functional beads were 
set to missing. A sample-wise call rate of 80% was applied, and color bias adjustment using smooth 
quantile normalization was performed. Finally, beta-mixture quantile normalization was performed on 
the probes (Bioconductor R package watermelon 99) to correct for the Inf I/Inf II distribution shift.  
Gene expression data 
Gene expression analysis of the a subset of the KKNMS cohort (n=319 DE1 MS cases) was 
performed using llumina HT-12 v4 Expression BeadChips and published and described previously in 
27. For a subset of the KORA cohort (n=1,002 F4 individuals) gene expression profiling was performed 
using the Illumina HT-12 v3 Expression BeadChips and described previously in 100. 
Statistical analysis of gene expression and methylation data 
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For the recMDD cohort, linear regression models were fit for each probe to test the relationship 
between the DNA methylation (beta values) and genotype (in dosage format) within 1Mb up- or 
downstream of the SNP using the R package MatrixEQTL 101. Sex, blood cell counts and genotype 
MDS components to correct for possible admixture effects were included as covariates. Significance 
after multiple testing was adjusted using a false discovery rate (FDR) of 5%.  
 
For the KORA cohort, the OmicAbel software 102 was used to test the association between 
methylation beta values and SNP dosage, adjusting for age, sex, and blood cell count. A total of 1,731 
individuals had valid methylation and genetic data. Significance was defined after Bonferroni 
correction at a p-value of 1e-14. To examine the relationship between genetic variation and gene 
expression in KORA (n=711 individuals with valid genetic and expression data), we first derived 
residuals for gene transcript expression using linear regression of log2-transformed gene transcript 
levels against sex, age, RNA integrity number, RNA amplification plate, and sample storage time. 
Expression residuals were then used as outcome variables in a linear regression model with SNP 
dosage as the independent variable. Data analysis was performed using MatrixEQTL and significant 
meQTLs were filtered at an FDR of 5%. 
 
For the analysis of association between genotype and expression levels in the KKNMS cohort, we 
used MatrixEQTL with sex, age, blood cell counts, and genotype MDS components as covariates. 
Significance after multiple testing was adjusted using an FDR of 5%. 
 
Using published QTL data from BIOS whole peripheral blood DNA of 3,841 and mRNA of 2,116 
healthy samples (eQTL, meQTL, eQTM), downloaded from http://genenetwork.nl/biosqtlbrowser, 
CMC eQTLs downloaded from https://www.synapse.org/#!Synapse:syn4622659, and GTEx eQTLs 
downloaded from https://gtexportal.org/home/datasets, we were able to intersect our deepSNPs and 
their LD proxies (r2≥0.5) with transcriptionally relevant data. The eQTLs obtained from GTEx were 
filtered on gene p<0.05 and eQTLs obtained from BIOS and CMC were filtered on FDR <0.05. We 
used permutation tests to determine if deepSNPs or their LD proxies were enriched in BIOS QTLs. 
For each phenotype, we compared the overlap of deepSNPs and BIOS QTL SNPs to the average 
overlap from 1,000 equally sized sets of regulatory SNPs and BIOS QTL SNPs. 
QTL network 
For the visualization of deepSNP-QTL interactions, we set up an Neo4j 103 instance. The Neo4j 
community edition version 3.4.0 was downloaded from https://neo4j.com. All DeepWAS results were 
inserted to the database. The graph structure consisted of genes, transcription factors, CpGs, SNPs, 
cell lines, and tissues that are connected to each other through dummy nodes representing each 
deepSNP. Dummy nodes are especially important in cases where a deepSNP is predicted to be 
active in more than one FU, e.g. TF1:CL1 and TF2:CL2. In this case, connecting these 4 elements 
directly to the deepSNP leads to ambiguity about the FU, which can be misinterpreted as TF1:CL2 or 
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TF2:CL1, since the information of the FU is lost. Using dummy nodes avoids this confusion by 
providing a SNP-FU link.  
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